公开(公告)号：US20230144122A1

公开(公告)日：2023-05-11

申请号：US17595013

申请日：2019-11-05

申请人： Jiangxi Caishi Pharmaceutical Technology Co., Ltd.

发明人： Qing SHAO ,  Libin GAN ,  Li CHEN

IPC分类号： C07D498/14

CPC分类号： C07D498/14 ,  C07B2200/13

摘要： Provided are crystals of (((R)-12′-((S)-7,8-difluoro-6,11-dihydrodibenzo[b,e]thiepin-11-yl)-6′,8′-dioxo-6′,8′,12′,12a′-tetrahydro-1′H,4′H-spiro[cyclopropane-1,3′-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazin]-7′-yl)oxy)methyl methyl carbonate, i.e. compound of Formula (1) or a solvate thereof and a preparation method therefor, the crystals comprising crystal form A, crystal form B, crystal form C, crystal form D, crystal form E, crystal form F, and single crystal. The crystal of the compound of Formula (1) or a solvate thereof can be individually used for clinical treatment or in combination with other anti-influenza drugs such as neuraminidase inhibitors, nucleoside drugs, or PB2 inhibitors, being capable of clinically curing influenza patients quickly, and having very good activity and good bioavailability compared to existing pyridone derivatives. In addition, the stability, hygroscopicity, and storability of the crystals meet the requirements for pharmaceutical use.